Loading...
NPI 1629495759 · Las Vegas, NV · Internal Medicine Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Manas Agastya is a internal medicine physician provider located in Las Vegas, Nevada. This profile covers 78 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Manas Agastya |
| Address | 1707 W Charleston Blvd Ste 230 |
| City | Las Vegas |
| State | NV |
| ZIP | 89102 |
| Taxonomy | Internal Medicine Physician |
| NPI Enumerated | March 26, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.6M |
| Medicaid | $430 |
Billing mix and service line: The provider's top Medicare revenue drivers are oncology and infusion services, with J9271 (pembrolizumab) at $739.2K (49.2% of Medicare revenue), J9299 (nivolumab) at $317.1K (21.1%), and chemotherapy administration 96413 at $68.3K (4.5%). This combination of high-volume immunotherapy agents and chemotherapy administration codes indicates the practice functions primarily as an outpatient oncology/infusion operation rather than a general primary care clinic.
Revenue concentration on Medicare: Medicare accounts for the vast majority of clinical revenue ($1.6M) and this revenue is highly concentrated—precomputed top 3 Medicare codes account for 74.9% of the provider's total Medicare revenue. By contrast, Medicaid revenue is negligible at $429, with the precomputed top 3 Medicaid codes accounting for 100.0% of that amount, indicating very little diversification across payers.
Payer mix and scale: The provider is effectively Medicare-dominant, with $1.6M in Medicare revenue versus $429 in Medicaid revenue; Medicaid activity is de minimis in scale relative to Medicare and does not represent a meaningful portion of the practice's business. This suggests payer risk and strategy will be heavily tied to Medicare reimbursement and oncology benefit dynamics.
Competitive standing for immunotherapy: Although J9271 (17.6K claims, $739.2K) and J9299 (16.7K claims, $317.1K) together drive the largest shares of revenue, their national rank/percentile positions are unremarkable (J9271: #522 of 1841, 71th percentile; J9299: #209 of 505, 59th percentile), implying the provider's immunotherapy volumes are typical among peers rather than dominant. The high revenue from these codes reflects the high per-unit cost of these agents, not uniquely large market share in immunotherapy.
Infusion and procedure intensity outlier signals: The provider shows above-typical chemotherapy administration intensity for certain infusion-related codes—96413 ranks #289 of 7514 (96th percentile; noted as "notably above typical national volume for this code") and the add-on 96417 ranks in the 95th percentile as well. These percentile signals point to materially higher-than-typical infusion throughput and frequent multi-drug or prolonged infusion sessions relative to national peers, consistent with an established outpatient infusion practice.
E/M services and practice mix: Office evaluation-and-management codes contribute a modest share of Medicare revenue but appear at high national percentiles—99214 (503 claims, $46.3K) ranks in the 90th percentile and 99215 (238 claims, $31.4K) in the 94th percentile—indicating a meaningful outpatient management component alongside infusion care. This suggests the practice blends same-day/clinic-based oncology management with infusion services, rather than solely dispensing medications.
Medicaid footprint and competitiveness: All reported Medicaid revenue comes from 99213 (15 claims, $435), which represents 100.0% of the provider's Medicaid revenue and ranks #2346 of 2476 in-state (4th percentile). That ranking and extremely small Medicaid dollar volume indicate the provider is a very minor participant in Nevada's Medicaid market and likely has minimal referral or contracting exposure to Medicaid.
Tenure and operational implications: The provider's NPI was enumerated 2014-03-26 (~12 years ago), signalling an established practice presence in Las Vegas. Combined with the heavy use of oncology infusions and biosimilar codes (e.g., Q5119, Q5122, Q5108 present in the Medicare mix), the pattern is consistent with a longstanding outpatient oncology/infusion center that has begun to incorporate biosimilars into its drug mix as part of care delivery and cost management.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
78 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 17,600 | $40 | $739.2K |
| J9299 | Injection, nivolumab, 1 mg | 16,690 | $20 | $317.1K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 680 | $100 | $68.3K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,140 | $20 | $47.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 500 | $90 | $46.3K |
| J0897 | Injection, denosumab, 1 mg | 1,920 | $20 | $34.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 240 | $130 | $31.4K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 290 | $100 | $27.6K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 210 | $130 | $27.5K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 220 | $90 | $20.3K |
Showing 1–10 of 78
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 78 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
78 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 11 | 40 | 13,000 | $40 | $625.8K |
| J9299 | 4 | 10 | 14,400 | $20 | $362K |
| 88185 | 2 | 10 | 5,240 | $20 | $97.7K |
| J0897 | 52 | 70 | 3,630 | $20 | $94.6K |
| Q5119 | 2 | 10 | 2,050 | $20 | $46.4K |
| Q5122 | 7 | 10 | 350 | $90 | $37.7K |
| 99233 | 1,027 | 1,150 | 150 | $90 | $26.8K |
| J9217 | 11 | 40 | 120 | $130 | $23.9K |
| 96413 | 2 | 70 | 210 | $100 | $23.7K |
| 99232 | 1,166 | 1,340 | 140 | $60 | $23.7K |
Showing 1–10 of 78
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 20 | $30 | $440 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,346 | 2,480 | 330 | $50 | $107.6K |
Other providers in the same ZIP code as Manas Agastya, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.